Datapoint: Merck-Seagen Deal Could Be in the Works

Merck & Co. is reportedly eyeing a $30 billion deal to acquire Seagen Inc., according to the Wall Street Journal. Merck already owns five million shares in the company. According to data from Evaluate Pharma, Seagen’s leading drug is Padcev, an antibody-drug conjugate made in partnership with Astellas. The drug is approved for the treatment of bladder cancer, where it holds covered or better status for 59% of all insured lives under the pharmacy benefit, and 81% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/20/22, and Evaluate Pharma.

0

0

0 Comments

0

0

• Datapoint